SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 193 filers reported holding SAGE THERAPEUTICS INC in Q2 2024. The put-call ratio across all filers is 0.24 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $814 | -42.1% | 75 | 0.0% | 0.00% | – |
Q1 2024 | $1,405 | -13.5% | 75 | 0.0% | 0.00% | – |
Q4 2023 | $1,625 | -54.9% | 75 | -57.1% | 0.00% | – |
Q3 2023 | $3,601 | -56.2% | 175 | 0.0% | 0.00% | – |
Q2 2023 | $8,228 | +12.1% | 175 | 0.0% | 0.00% | – |
Q1 2023 | $7,343 | +104800.0% | 175 | -5.4% | 0.00% | – |
Q4 2022 | $7 | -99.9% | 185 | 0.0% | 0.00% | – |
Q3 2022 | $7,000 | +40.0% | 185 | +5.7% | 0.00% | – |
Q2 2022 | $5,000 | -16.7% | 175 | -9.8% | 0.00% | – |
Q1 2022 | $6,000 | -14.3% | 194 | +10.9% | 0.00% | – |
Q4 2021 | $7,000 | 0.0% | 175 | 0.0% | 0.00% | – |
Q3 2021 | $7,000 | -30.0% | 175 | 0.0% | 0.00% | – |
Q2 2021 | $10,000 | -23.1% | 175 | 0.0% | 0.00% | – |
Q1 2021 | $13,000 | -13.3% | 175 | 0.0% | 0.00% | – |
Q4 2020 | $15,000 | +36.4% | 175 | 0.0% | 0.00% | – |
Q3 2020 | $11,000 | +57.1% | 175 | 0.0% | 0.00% | – |
Q2 2020 | $7,000 | +40.0% | 175 | 0.0% | 0.00% | – |
Q1 2020 | $5,000 | -66.7% | 175 | -14.6% | 0.00% | -100.0% |
Q4 2019 | $15,000 | – | 205 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
DAFNA Capital Management LLC | 99,306 | $14,027,000 | 5.76% |
Casdin Capital, LLC | 312,000 | $44,070,000 | 5.36% |
Palo Alto Investors LP | 840,372 | $118,703,000 | 4.80% |
BB BIOTECH AG | 1,071,373 | $151,331,000 | 4.00% |
TRV GP II, LLC | 37,362 | $5,277,000 | 3.10% |
Eversept Partners, LP | 43,621 | $6,161,466 | 2.70% |
RA Capital Management | 350,933 | $49,569,000 | 2.65% |
Eventide Asset Management | 494,000 | $69,778,000 | 2.56% |
OAK RIDGE INVESTMENTS LLC | 241,099 | $34,055,000 | 1.88% |
SUFFOLK CAPITAL MANAGEMENT LLC | 93,000 | $13,136,000 | 1.87% |